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Abstract: Nephrotic syndrome represents the clinical situation characterized by presence of massive
proteinuria and low serum protein caused by a variety of diseases, including minimal change nephrotic
syndrome (MCNS), focal segmental glomerulosclerosis (FSGS) and membranous glomerulonephropathy.
Differentiating between diagnoses requires invasive renal biopsies in general. Even with the biopsy,
we encounter difficulties to differentiate MCNS and FSGS in some cases. There is no other better option
currently available for the diagnosis other than renal biopsy. MicroRNAs (miRNAs) are no-coding
RNAs of approximately 20 nucleotides in length, which regulate target genes in the post-transcriptional
processes and have essential roles in many diseases. MiRNAs in serum and urine have been shown as
non-invasive biomarkers in multiple diseases, including renal diseases. In this article, we summarize the
current knowledge of miRNAs as the promising biomarkers for nephrotic syndrome.
Keywords: microRNA; nephrotic syndrome; biomarker; minimal change nephrotic syndrome; focal
segmental glomerulosclerosis; membranous glomerulonephropathy
1. Introduction
Nephrotic syndrome (NS) is defined as massive proteinuria and low serum total
protein due to the disrupted function of glomerular filtration barrier [1,2]. It may cause
multiple metabolic effects and complications, including hypercoagulability, bacterial infec-
tion and acute kidney injury [2]. The underlying pathological etiologies of NS are diverse.
For younger ages, the etiology of NS is more likely to be from minimal change nephrotic
syndrome (MCNS) and focal segmental glomerulosclerosis (FSGS), while there are varieties
of etiologies for older ages, including MCNS, FSGS, membranous glomerulonephropathy
(MGN) and others [3,4]. Accumulating evidence suggests that MCNS and FSGS may be due
to the circulating factors [5,6]. For example, Sharma et al. reported that a single injection of
plasma obtained from FSGS patients into rats caused transient proteinuria, suggesting that
circulating factors might be involved in the pathogenesis in FSGS [7]. Wei et al. reported
that soluble form of the urokinase receptor (suPAR), which was shown to activate podocyte
integrin β3, might be the cause of FSGS [8]. However, it is still controversial whether
suPAR is the pathogenetic of FSGS, and exact pathophysiology of FSGS and MCNS are
still uncertain. In the point of prognosis of NS, patients with MCNS are generally steroid
sensitive, while patients with FSGS are more likely to be steroid resistant. Although renal
biopsy is the standard method to differentiate these diseases especially in adult patients, it
is an invasive examination with possible complications. In addition, it is difficult to make
the accurate diagnosis in some cases, especially because the glomerular segmental sclerosis
in FSGS patients is focal and sometimes patients need repeated biopsies for the accurate di-
agnosis. Therefore, non-invasive biomarkers may be used to differentiate between different
etiologies of NS. In addition, ideal biomarkers also reflect disease activity for monitoring
response to treatment, progression and determining disease prognosis.
MicroRNAs (miRNAs) are single-stranded non-coding RNAs, which are an average
of 22 nucleotides in length, and which regulate target genes in the post-transcriptional
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processes [9,10]. In mammals, more than a thousand different miRNAs have been identi-
fied [9,10] and these miRNAs are reported to be involved in multiple biological cellular
and molecular processes, including cell proliferation, apoptosis and differentiation [11]. In
most cases, miRNAs interact with three prime untranslated regions (3′-UTR) in the target
genes, which results in the degradation of mRNAs or translational inhibition [12]. Aberrant
expression of miRNAs has been reported to be associated with human diseases [12,13].
miRNAs have been reported to be secreted into biological fluid, including serum and urine.
miRNAs are also carried in the extracellular vesicles, including exosomes and microvesicles,
which are transferred into recipient cells, in which gene translations are regulated as the
cell–cell communication. miRNAs have been widely reported as promising biomarkers
for many diseases. In fact, they have been shown as non-invasive biomarkers in multiple
diseases including cancers and renal diseases [14–17]. Because miRNAs may directly
be associated with pathogenesis of some types of NS, to analyze miRNA profiles in NS
patients is not only for the diagnosis for the specific diseases, but also for understanding
and elucidating the disease pathogenesis and even for establishing novel therapies. There
is accumulating evidence for novel and non-invasive biomarkers of miRNAs as liquid
biopsy in NS. In this review article, we summarize the current knowledge about miRNAs
as promising biomarkers for NS.
2. miRNAs in Nephrotic Syndrome
There are several reports that have analyzed miRNAs in NS patients (Table 1). Luo
et al. analyzed serum and urine miRNAs in child idiopathic NS patients and indicated
increased levels in serum miR-30a-5p, miR-151-3p, miR-150, miR-191 and miR-19b as well
as urine miR-30a-5p in NS patients compared to healthy controls [18]. Zhang et al. also
analyzed child NS patients and reported the increased levels of peripheral blood miR-17-5p
in child NS patients compared to healthy controls [19]. Chen et al. analyzed urine samples
from child NS patients by high-throughput illumina sequencing via synthesis technology
and reported that levels of urine miR-194-5p, miR-146b-5p, miR-378a-3p, miR-23b-3p and
miR-30a-5p were higher compared to age and sex-matched healthy controls, and these
miRNAs were decreased during the clinical remission period [20]. They also indicated
that levels of urine miR-194-5p and miR-23b-3p were positively correlated with levels of
urine protein, and proposed that urine miR-194-5p and miR-23b-3p can be the potential
biomarkers for diagnosis and monitoring in NS patients. Wang el al. reported that levels
of serum miR-503 in child NS patients measured by qPCR were lower than in healthy
controls [21]. They used rat mesangial cells to explore the effect of miR-503, and indicated
that miR-503 may contribute to the aberrant proliferation by targeting cyclin E, which was
found to be the target of miR-503 by luciferase reporter assay. In addition to the analysis
of biological fluid, kidney tissues have also been applied for the analysis of miRNAs. Lu
et al. analyzed kidney tissues from child NS patients in different subtypes, and indicated
that miR-191 levels were higher and miR-151-3p levels were lower in all NS subtypes
compared to the controls [22]; that is the different trend as increased levels in both miR-191
and miR-151-3p under the analysis of serum [18]. These differences might be because of
the different regulatory mechanism between expression in tissue and secretion into blood
or urine. Further exploration might uncover the pathophysiology of podocyte injury and
disease mechanism of NS.
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Table 1. MiRNAs in nephrotic syndrome.






serum Child NS healthy control ↑ [18]
miR-30a-5p urine Child NS healthy control ↑ [18]






urine Child NS healthy control ↑








miR-503 serum Child NS healthy control ↓ [21]
miR-191 kidney Child NS healthy control ↑ [22]
miR-151-3p kidney Child NS healthy control ↓ [22]
miR-638 urine NS non-NS control ↓ [23]







serum NS healthy control ↑




miR-181a serum NS healthy control ↑ [26]
NS: nephrotic syndrome; ↑: increase; ↓: decrease.
In the adult study, Wang et al. analyzed the urine sediment from patients with
NS caused by diabetes nephropathy (DN), MCNS, FSGS and MGN, and reported that
the levels of urine miR-638 in NS patients were lower than non-nephrotic controls, and
that urine miR-29a, miR-192 and miR-200c levels were significantly different between
diagnostic groups [23]. Specifically, urine miR-200c levels in MCNS and FSGS patients
were higher than patients with other diagnosis, while urine miR-192 levels were lower in
DN patients compared to patients with other diagnosis. Zapata-Benavides et al. reported
that serum miR-16-1 levels in NS patients analyzed by qPCR were lower than healthy
controls [24]. Teng et al. also investigated the miRNA profile using serum samples with
qPCR verification and reported that serum miR-181a, miR-210, miR-30a, miR-942, miR-192
and miR-586 levels were upregulated in NS patients [25]. In addition, serum miR-30a
levels in treatment-resistant NS patients were higher than treatment-sensitive NS patients,
indicating the use of miR-30a levels to differentiate between pathological subtypes or
predict prognosis. Another report using qPCR indicated the increase in serum miR-181a
levels in NS patients compared to healthy controls [26].
This increase and/or decrease in miRNAs might be the reflection of podocyte injury or
associated with pathophysiology of the diseases. It is reported that podocyte cytoskeleton
is regulated by several miRNAs, including miR-30, miR-132, miR-134 and miR-29a [27].
The increase in serum and urine miR-30a-5p levels in child NS might be associated with the
disorder of podocyte cytoskeleton [18,20]. Although the changes in the expression of these
miRNAs in NS patients have been shown, further reports are required to differentiate the
causes of NS, such as MCNS, FSGS and MGN. Next, we summarize the miRNA analysis of
specific type of NS.
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3. miRNAs in Membranous Glomerulonephropathy
MGN is one of the important causes of NS, especially for adults. Although the
pathogenesis of MGN is not fully understood, recent studies revealed the autoantibodies
to the M-type receptor for phospholipase A2 receptor 1 (PLA2R1) [28], thrombospondin
type-1 domain-containing 7A (THSD7A) and neural epidermal growth factor-like 1 protein
(NELL-1) as the pathogenesis of MGN [28–30]. PLA2R1 was found to be expressed on
podocytes in normal human glomeruli and to be colocalized with IgG4 in immune deposits
in glomeruli from MGN patients, indicating that PLA2R1 may be a major antigen in
MGN [28]. Similarly, THSD7A, also found to be expressed on normal podocytes, was
shown to be highly expressed in podocyte that was colocalized with IgG4 in MGN patients
without anti-PLA2R1 antibodies [30]. In addition, IgG eluted from the frozen kidney in a
MGN patient with positive anti-THSD7A antibodies specifically recognized recombinant
THSD7A by immunoblot analysis, indicating that THSD7A might be involved in the
pathogenesis of MGN [30]. More recently, NELL-1 was shown to be involved in the
pathogenesis of MGN negative for both PLA2R1 and THSD7A antibodies. Unlike, PLA2R1
and THSD7A, NELL-1 is barely detectable in normal glomeruli, but is highly expressed in
NELL-1-associated MGN podocytes, colocalizing with IgG [29]. In addition, immunoblot
analysis revealed the reactivity to NELL-1 in sera from NELL-1-associated MGN, indicating
the presence of anti-NELL-1 antibodies. Therefore, monitoring circulating antibodies for
these markers might be the useful option for the diagnosis or monitoring in patients
with MGN. Indeed, Guo et al. reported that more than 70% idiopathic MGN patients
were positive for PLA2R antibody and that the titer of serum anti-PLA2R antibody was
correlated with urine proteinuria and serum albumin levels of pre- and post- therapeutic
values in idiopathic MGN patients, suggesting that serum anti-PLA2R antibody may guide
clinical diagnosis and treatment as well as the prognostic clues [31]. Nevertheless, quite a
few patients with primary MGN are negative for PLA2R, THSD7A and NELL-1 antibodies;
thus, further exploration for finding other biomarkers, including miRNAs, is still required.
There are a limited number of publications of miRNAs in MGN patients (Table 2).
Chen et al. analyzed the comprehensive miRNA profile using high-throughput sequencing
technology in peripheral blood lymphocytes from MGN patients compared to healthy
controls and reported that 20 kinds of miRNAs levels were increased or decreased in MGN
patients compared to the healthy controls [32]. Among these miRNAs, the levels of miR-217
were dramatically downregulated. Based on the report, Li et al. analyzed the expression
of plasma and kidney miR-217 in MGN patients and reported the decreased miR-217 ex-
pressions in plasma and kidney tissues in MGN patients compared to control patients [33],
and also demonstrated that the downregulation of miR-217 may cause podocyte apopto-
sis via targeting TNF superfamily member 11 (TNFSF11). miR-186 expression was also
reported to be downregulated in MGN kidney tissues and to be associated with podocyte
apoptosis [34]. On the other hand, Hejazian et al. reported the increase in miR-30c levels
from peripheral blood mononuclear cells and plasma miR-186 levels in MGN patients
compared to FSGS patients and healthy controls [35]. Although samples analyzed in these
two studies were different, further analysis might be required to make conclusion. Rahbar
et al. analyzed the expression pattern of the glucocorticoid receptors α and β, and their
epigenetic regulators, miR-24, miR-30a and miR-370 in peripheral blood mononuclear cells,
and reported that the increase in miR-30a and miR-370 levels as well as the decrease in
miR-24 levels were observed in MGN patients compared to FSGS patients, while no signifi-
cant differences in glucocorticoid receptors α and β expressions were observed between
MGN, FSGS and healthy controls, indicating that dysregulation levels of glucocorticoid
receptors α and β were not attributed to steroid resistance [36]. Liu et al. found that
miR-130-5p potentially regulates PLA2R1 and, thus, investigated the correlation between
miR-130-5p and MGN, and reported the decreased expression of miR-130-5p in kidneys
of MGN patients [37]. They conducted animal experiments and demonstrated that the
decrease in miR-130a-5p expression may increase PLA2R expression, thereby inducing
podocyte apoptosis. Zhang et al. revealed the increased expression of urine miR-193a
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in MGN patients compared to healthy controls, and higher urine miR-193a levels were
associated with poor renal survival [38]. Zhou et al. conducted the microarray analysis
and reported that serum and urine miR-195-5p, miR-192-3p, miR-328-5p levels and their
target genes, PPM1A, RAB1A and BRSK1 may be the potential biomarkers for MGN [39].
Barbagallo et al. analyzed miRNA profile and their target mRNAs from MGN kidney
tissues and indicated that let-7a-5p, let-7b-5p, let-7c-5p, let-7d-5p, miR-107, miR-423-5p,
miR-516-3p, miR-532-3p and miR-1275 levels were upregulated, and miR-129-3p levels
were downregulated in MGN kidney samples compared to unaffected kidney tissues
undergoing nephrectomy for renal cancer [40]. They also indicated that these miRNAs
may target interleukin 6 and MYC mRNAs, that might be involved in the pathogenesis of
MGN, including cell cycle, proliferation and apoptosis.
Table 2. MiRNAs in membranous glomerulonephropathy.
miRNA Analyte Comparison Levels Mechanism Reference
miR-217 Peripheral blood lymphocytes healthy control ↓ [32]
miR-217 plasmakidney healthy control ↓ podocyte apoptosis [33]
miR-30c Peripheral bloodmononuclear cells
FSGS
healthy control ↑ [35]
miR-186 plasma FSGShealthy control ↑ [35]
miR-30a Peripheral bloodmononuclear cells FSGS ↑ [36]
miR-24 Peripheral bloodmononuclear cells
FSGS
healthy control ↓ [36]
miR-370 Peripheral bloodmononuclear cells
FSGS
healthy control ↑ [36]
miR-186 kidney healthy control ↓ podocyte apoptosis [34]
miR-130-5p kidney control patients ↓ PLA2R-podocyte apoptosis [37]































FSGS: focal segmental glomerulosclerosis; PLA2R: phospholipase A2 receptor; ↑: increase; ↓: decrease.
In spite of the accumulating evidence, most of these reports only analyzed specific
miRNAs and there were only three reports in which comprehensive miRNA analysis by
microarray was conducted [32,39,40]. In addition, most of these studies analyzing miRNAs
have been compared MGN patients to healthy controls, not to other NS diseases, such as
MCNS and FSGS, thus these miRNA profile changes might not be directly associated with
MGN pathogenesis, but might be the common trend in NS patients. Further validation
studies between MGN and other causes of NS is still required to make conclusions.
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4. Biomarkers in Minimal Change Nephrotic Syndrome and Focal Segmental
Glomerulosclerosis
MCNS is the most common disease to cause NS in children. Since renal biopsy is un-
likely to be conducted in child MCNS patients without atypical features, such as hematuria
and steroid-resistance, non-invasive tools to differentiate MCNS from other causes of NS—
especially FSGS, which is another important cause of NS in children—are desired. Recently,
Inoue-Torii et al. reported that the levels of urine semaphorin3a are associated with disease
activity in MCNS patients [41]. Semaphorin3a is the secreted protein that is involved in
several biological functions. In mammalian kidneys, semaphorin3a is expressed in the
glomerular podocytes and tubular cells, and is involved in the pathogenesis in podocyte
injury. For example, semaphorin3a has been reported to cause podocyte apoptosis through
the activation of c-Jun N-terminal kinase (JNK) signaling [42], indicating that semaphorin3a
may be identified not only as the biomarker for MCNS patients but also as the therapeutic
target in NS. In addition to semaphorin3a, several possible biomarkers for the diagnosis
as well as the pathogenesis of MCNS have been reported. CD80 (also known as B7.1)
is one of the possible markers. CD80 is the dendrite-associated receptor which induces
co-stimulatory signaling in T cells [43] and is a transmembrane glycoprotein expressed
in podocytes in the kidneys [44]. Urine CD80 levels were reported to be upregulated
in the relapse of MCNS [45]. The administration of lipopolysaccharide (LPS) into mice
caused rapid onset of proteinuria with CD80 expression in podocytes, and the onset of
proteinuria caused by LPS was prevented when injected into CD80 knockout mice [46]. In
addition, serum from MCNS patients under relapse stimulated CD80 expression in cultured
podocyte, suggesting that CD80 might be involved in the pathogenesis in MCNS [44]. Inter-
leukin 13 (IL-13), that is the cytokine secreted from Th2 cells, is another potent biomarker in
MCNS. The increase in IL-13 mRNA in CD4(+)-CD8(+) T cells from child steroid-sensitive
NS patients was reported [47]. Subsequently, serum IL-13 levels were found to be increased
in child NS patients [48]. Importantly, there are several reports indicating that IL-13 might
cause podocyte injury and MCNS. For example, it is reported that IL-13 decreased the
function of glomerular filtration barrier in the dose dependent manner [49]. In addition,
overexpression of IL-13 caused MCNS-like glomerulopathy in rats, suggesting the possible
involvement in the pathogenesis for MCNS [50]. Hemopexin was another possible marker
for the diagnosis of MCNS. The decrease in serum hemopexin with higher protease activity
in MCNS under relapse was reported [51]. In addition, the injection of hemopexin into
rats caused reversible proteinuria [51]. Since hemopexin has been reported to induce
nephrin-dependent actin cytoskeleton reorganization in podocytes [52], hemopexin might
be another factor to be involved in the pathogenesis of MCNS. Finally, angiopoietin-like
4 (Angptl-4), a secreted glycoprotein, has been reported as another potent marker [53].
Angptl-4 is highly expressed in the adipose tissue and liver, and is known to be associated
with tumor metastasis [54]. It is reported that the expression of angptl-4 in serum and
podocytes in MCNS as well as the rodent podocytes under the treatment with LPS or
puromycin aminonucleoside (PAN) were increased [53]. In addition, podocyte-specific
overexpression of angptl-4 in rats caused nephrotic range of proteinuria. Interestingly,
adipose tissue-specific angptl-4 overexpression did not cause proteinuria while there were
increased levels of circulating angptl-4, indicating the importance of podocyte angptl-4
expression under NS [53]. However, subsequent reports from same group revealed that
the increased levels of angptl-4 were also observed in other NS patients, including FSGS
and MGN [55]. Although these several biomarkers have been reported, further analysis is
still required to make conclusions.
FSGS is another important disease to cause NS. It is known that podocyte damage
plays the essential role in the development of FSGS. There are varieties of different causes
of FSGS, primary and secondary FSGS, including genetic, adaptive, APOL1-associated,
virus-associated, and medication/toxin-associated FSGS [56]. However, the underlying
causes are still unknown in most cases, which are defined as primary or idiopathic FSGS. As
described previously, the circulating factors, which may cause podocyte injury or increase
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the glomerular permeability, are believed to be the pathogenetic for FSGS. Wei et al.
reported suPAR as the circulating factor to cause FSGS. The urokinase-type plasminogen
activator receptor (uPAR) has been known to have important roles for cell migration. uPAR
might be shed from cell membrane, called suPAR, which might cause podocytopathy as
circulating factors. Indeed, it is reported that the overexpression of uPAR in podocytes
as well as the administration of suPAR in mice caused proteinuria [57]. Increased suPAR
levels in FSGS patients were also reported in meta-analysis reports [58,59]. However,
several conflicting results have also been reported [60–62]; thus, it is still controversial
whether suPAR is involved in the pathogenesis of FSGS. Therefore, further exploration
of the pathogenesis as well as the specific biomarkers are still required. In the point of
miRNAs, there is accumulating evidence as the biomarker in MCNS as well as FSGS (Table 3).
Table 3. MiRNAs in minimal change nephrotic syndrome and focal segmental glomerulosclerosis.
miRNA Analyte Disease Comparison Levels Mechanism Reference






plasma MCNS FSGShealthy control ↑ [63]
miR-1225-5p urine MCNS FSGShealthy control ↑ [63]
























kidney FSGS healthy control ↓ [66]















↑ regulation ofWT1 [70]
miR192
miR-205 serum FSGS MCNS ↑ [71]
miR-10a
miR-30d urine FSGS healthy control ↑ [72]
MCNS: minimal change nephrotic syndrome; FSGS: focal segmental glomerulosclerosis; NS: nephrotic syndrome; DN: diabetic nephropathy;
WT1: Wilm’s tumor-1; ↑: increase; ↓: decrease.
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5. miRNAs in Minimal Change Nephrotic Syndrome and Focal Segmental
Glomerulosclerosis
Lu et al. analyzed renal tissues from child NS patients in different subtypes, and
indicated that the expressions of miR-150 were lower in MCNS compared to some other
types of NS, suggesting the possibility that miR-150 might be the indicator to differentiate
MCNS from other types of NS [22]. On the other hand, Qi et al. reported increased miR-150
expressions in kidneys from FSGS patients compared to healthy controls [67]. They also
indicated the protective effect of miR-150 inhibitor for doxorubicin-induced FSGS mouse
model through anti-fibrosis and anti-inflammation mechanisms. These reports might reflect
the protective effect of miR-150 inhibition against podocyte injury.
Yang et al. analyzed renal tissues from FSGS patients and indicated increased ex-
pression of miR-135a [64]. They also indicated the increased expression of miR-135a in
doxorubicin-induced mouse kidneys. In addition, they demonstrated that the ectopic
expression of miR-135a resulted in severe podocyte injury and disarray of podocyte cy-
toskeleton while podocyte-specific expression of transient receptor potential canonical 1
(TRPC1) was able to reverse the effect of miR-135a in cultured podocytes, demonstrating
the dependency of TRPC1. In another study, Zhang et al. compared plasma miRNAs
from FSGS patients, MGN patients, diabetic nephropathy (DN) patients and healthy con-
trols, and revealed that plasma miR-125b, miR-186 and miR-193a-3p levels were higher
in FSGS patients than in patients with other diseases [65]. In addition, plasma miR-125b
and miR-186 levels declined markedly in patients with FSGS with complete remission
while there was no decrease in FSGS patients with steroid resistant. Importantly, plasma
miR-125b and miR-186 levels were not upregulated in MGN and DN patients, suggesting
the possibility of these miRNAs as the specific biomarkers for FSGS. Nevertheless, there
was no comparison between MCNS and FSGS, which may be the limitation in the study.
Interestingly, plasma miR-186 levels, but not miR-125b levels, were positively correlated
with degrees of proteinuria in FSGS patients [65]. Meanwhile, as described previously,
Hejazian et al. reported the increase in plasma miR-186 levels in MGN patients, not in
FSGS patients, compared to healthy controls, indicating that it is still controversial [35].
Xiao et al. reported, using qPCR-based high-throughput miRNA profile, that plasma
miR-17, miR-451, miR-106a and miR-19b levels were downregulated in FSGS patients
compared to healthy controls. They also indicated that plasma miR-17, miR-451 and miR-
106a levels were associated with remissions of FSGS [68]. They suggested that miR-106a
might target phosphatase and tensin homolog (PTEN), Bcl-2-like protein 11 (BCL2L11)
and C-X-C motif chemokine ligand 14 (CXCL14), thereby regulating podocyte apoptosis.
Although they compared FSGS patients to other diseases, including IgA nephropathy,
MGN and mesangial proliferative glomerulonephritis, MCNS patients were not included
in the study.
For the differential diagnosis of MCNS and FSGS, miRNA comparison between these
diseases is required. Gebeshuber et al. reported that miR-193a expressions in FSGS kidneys
were upregulated compared to the kidneys from healthy controls and other glomerular
diseases, including MCNS [70]. They reported that the overexpression of miR-193a in mice
rapidly induced FSGS. miR-193a may target Wilms’ tumor protein (WT1) necessary for
podocyte homeostasis. They concluded that miR-193 might be involved in the pathogenesis
of FSGS and be the therapeutic target. Cai et al. reported that serum miR-192 and miR-205
levels were higher in FSGS patients compared to MCNS patients [71]. Levels of serum miR-
192 and miR-205 were correlated with proteinuria in FSGS patients while miR-192 levels,
not miR-205 levels, were correlated with proteinuria in MCNS. In addition, serum miR-192
levels were correlated with interstitial fibrosis in FSGS patients. In a comprehensive miRNA
analysis between MCNS and FSGS, Ramenzani et al. compared plasma and urine miRNAs
from FSGS patients, MCNS patients and healthy controls using Affymetrix GeneChip
miRNA 3.0 arrays, and reported that plasma miR-30b, miR-30c, miR-34b, miR-34c and miR-
342 levels, as well as urine miR-1225-5p levels, were higher in MCNS patients compared to
FSGS patients and controls [63]. On the other hand, urine miR-1915 and miR-663 levels
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were lower and urine miR-155 levels were higher in FSGS patients compared to MCNS
patients and the controls. Taken together, these results suggest that plasma miR-30, miR-34
and miR-342 as well as urine miR-1225 might be the potent diagnostic biomarkers for
MCNS while urine miR-1915, miR-663 and miR-155 might be the potent biomarkers for
FSGS.
Among these markers, miR-30 is worth focusing on since there are a lot of publications
under the analysis of NS. As described, several reports indicated the increase in serum
or urine miR-30 levels [18,20,25] in NS patients as well as the higher serum miR-30 levels
in MCNS compared to FSGS [63]. How about the miR-30 expression in FSGS? Hajazian
et al. reported no significant difference in plasma miR-30c levels between FSGS patients
and healthy controls [35]. On the other hand, Wu et al. reported that miR-30 family, miR-
30a, miR-30b, miR-30c, miR-30d and miR-30e, in FSGS glomeruli were all downregulated
compared to healthy controls [66]. Zhang et al. analyzed urine miRNAs in FSGS patients
by the TaqMan Low Density Array as well as RT-qPCR and indicated that urine miR-196a,
miR-30a-5p and miR-490 levels were higher in FSGS patients compared to the remission
period [69], indicating that these miRNAs are associated with disease activity of FSGS. In
addition, urine miR-30a-5p levels were shown to predict the response to steroid therapy
in FSGS patients, indicating the possible biomarker for disease monitoring. Wang et al.
reported that urine miR-10a and miR-30d levels in FSGS patients were higher compared to
healthy controls [72]. Taken together with these reports, urine miR-30 levels, not serum
miR-30 levels, may be increased in FSGS patients while serum miR-30 levels may be
increased in MCNS patients. Increased urine miR-30 levels in FSGS patients might be
the reflection of the increase in urine podocyte detached from the glomeruli. In this case,
we may explain the expression pattern difference between reports, diseases and types of
analyte. miR-30 might be indispensable for the maintenance of podocyte integrity since
miR-30 family has been reported to be podocyte protective [73]. For example, Wu et al.
reported that miR-30 family may protect from apoptosis by targeting Notch1 and p53 [66].
miR-30 family may also promote actin fiber stability in podocytes through the regulation
of calcium/calcineurin signaling by targeting transient receptor potential cation channel
subfamily C member 6 (TRPC6), protein phosphatase 3 catalytic subunit alpha (PPP3CA),
protein phosphatase 3 catalytic subunit beta (PPP3CB), protein phosphatase 3 regulatory
subunit alpha (PPP3R1) and nuclear factor of activated T cells 3 (NFATC3) [74,75]. Lang
et al. also demonstrated, using podocyte-specific miR-30 knockdown mice, that miR-30 may
prevent uPAR-integrin β3 (ITGB3) signaling through calcineurin-NFATC pathway, thereby
protect podocytes [76]. miR-30 has also been reported to be podocyte protective against
aldosterone-induced podocyte apoptosis and mitochondrial dysfunction through targeting
BCL2 interacting protein 3 like (BNIP3L) [77]. Based on these reports, targeting miR-30
might be the therapeutic target for podocyte protection as well as diagnostic biomarkers
for NS.
6. Future Requirement for Further Exploration
In spite of the accumulating evidence, there are still several limitations. First, there are
multiple pathological conditions even in the same disease. For example, under the analysis
of FSGS, there are varieties of different types of FSGS, primary and secondary FSGS, includ-
ing genetic, adaptive, APOL1-associated, virus-associated, medication/toxin-associated
FSGS [56], thus FSGS contains different types of etiology, that make the systematic analysis
more difficult. There are also different types of variant in the point of pathology among
FSGS patients, including collapsing, tip, perihilar, cellular and not otherwise specified
(NOS) [56]. Since these different causes of FSGS and different pathological variant might
have the different serum and urine miRNA profiles, we need to keep in mind that FSGS
contains these varieties of disease area and, thus, it is sometimes hard to interpret the data.
Second, there are two miRNA arms from the same precursor. miRNAs from 5′ and
3′ arms were annotated using the -5p and -3p suffixes [78]. Normally, one miRNA arm
is served as the dominant miRNA while another miRNA arm is usually degraded [79].
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However, in some cases, both arms are present and target different mRNAs [80,81]. It is
also reported that -5p and -3p miRNAs might be biologically different in terms of stability
and functionality [82]. In addition, the preference of -5p and -3p is not always consistent
depending on tissue types, stages of development and different diseases, suggesting the
presence of some regulatory mechanisms [83]. Therefore, miR-5p/miR-3p ratio validations
in NS might be another possible biomarkers. Considering these published reports, some
reports distinguished -5p and -3p, while others did not. It would be better to account the
-5p and -3p as different biomarkers, and to analyze, respectively.
Finally, there are a lot of different results that have come from the various studies
as described. There might be several reasons. One of the most essential reasons for this
point might be that not so many reports conducted the comprehensive miRNA analysis
for example by microarray analysis, and most of the published reports focused on specific
miRNAs known to be associated with NS. In addition, different analyte, including serum,
plasma, peripheral blood mononuclear cells, urine and kidney tissues, as well as the
different comparison, such as healthy controls or other NS diseases might cause the different
profile results. The analysis in child NS or adult NS patients may cause the different results
as well. In addition, sample size were very low in some reports. It would be required to
understand these limitations and it would be better to conduct more comprehensive and
large-scale miRNA analysis in NS patients.
7. Conclusions
As reviewed, there is accumulating evidence that indicates potential tools of miRNAs
as biomarkers for NS. Nevertheless, further analysis with higher numbers and appropriate
measurements of miRNAs are still required to assess the reliable tool of miRNAs in
the diagnosis, disease activity and prognosis. They are promising since these miRNA
data might be used not only for the diagnostic or prognostic biomarkers but also for
understanding the pathogenesis of podocyte injury and the specific etiologies of MCNS,
FSGS and MGN.
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